JP2020534540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534540A5 JP2020534540A5 JP2020516740A JP2020516740A JP2020534540A5 JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5 JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020516740 A JP2020516740 A JP 2020516740A JP 2020534540 A5 JP2020534540 A5 JP 2020534540A5
- Authority
- JP
- Japan
- Prior art keywords
- napi2b
- cancer
- seq
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 21
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 21
- 239000000611 antibody drug conjugate Substances 0.000 claims description 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 230000004043 responsiveness Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 238000010191 image analysis Methods 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 claims description 2
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims description 2
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 claims description 2
- 101710159262 Transcription termination factor 1 Proteins 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- -1 napsin A Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 238000000399 optical microscopy Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561107P | 2017-09-20 | 2017-09-20 | |
| US62/561,107 | 2017-09-20 | ||
| US201762571397P | 2017-10-12 | 2017-10-12 | |
| US62/571,397 | 2017-10-12 | ||
| US201862718692P | 2018-08-14 | 2018-08-14 | |
| US62/718,692 | 2018-08-14 | ||
| PCT/US2018/051951 WO2019060542A2 (en) | 2017-09-20 | 2018-09-20 | COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B TARGETING THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534540A JP2020534540A (ja) | 2020-11-26 |
| JP2020534540A5 true JP2020534540A5 (enExample) | 2021-10-28 |
| JP7279026B2 JP7279026B2 (ja) | 2023-05-22 |
Family
ID=63963394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516740A Active JP7279026B2 (ja) | 2017-09-20 | 2018-09-20 | Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11596694B2 (enExample) |
| EP (1) | EP3685166A2 (enExample) |
| JP (1) | JP7279026B2 (enExample) |
| KR (1) | KR20200055770A (enExample) |
| CN (1) | CN111492246A (enExample) |
| AU (1) | AU2018337947A1 (enExample) |
| BR (1) | BR112020005390A2 (enExample) |
| CA (1) | CA3075798A1 (enExample) |
| IL (1) | IL273252B2 (enExample) |
| MX (1) | MX2020003214A (enExample) |
| TW (1) | TW201929906A (enExample) |
| WO (1) | WO2019060542A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202035452A (zh) | 2018-08-17 | 2020-10-01 | 美商梅爾莎納醫療公司 | 靶向ＮａＰｉ２ｂ之聚合物抗體－藥物共軛體和使用彼之方法 |
| CA3149482A1 (en) | 2019-08-02 | 2021-02-11 | Mersana Therapeutics, Inc. | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer |
| EP4051320A1 (en) | 2019-10-30 | 2022-09-07 | CIS Pharma AG | Biocompatible polymeric drug carriers for delivering active agents |
| JP7846624B2 (ja) | 2020-01-09 | 2026-04-15 | メルサナ セラピューティクス インコーポレイテッド | ペプチド含有リンカーとの部位特異的抗体－薬物コンジュゲート |
| BR112022019919A2 (pt) | 2020-04-02 | 2023-02-14 | Mersana Therapeutics Inc | Conjugado de anticorpo-fármaco compreendendo agonistas de sting |
| AU2021321586A1 (en) | 2020-08-07 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Therapeutic targeting of phosphate dysregulation in cancer via the XPR1:KIDINS220 protein complex |
| CN116830204B (zh) * | 2021-02-08 | 2026-04-14 | 株式会社岛津制作所 | 估计装置、学习装置、优化装置、估计方法、学习方法以及优化方法 |
| JP2025535238A (ja) * | 2022-10-19 | 2025-10-24 | ザイムワークス ビーシー インコーポレイテッド | 抗ＮａＰｉ２ｂ抗体及び使用方法 |
| TW202421137A (zh) * | 2022-10-19 | 2024-06-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 靶向ＮａＰｉ２ｂ之抗體—藥物結合物及使用方法 |
| TW202530268A (zh) * | 2023-10-19 | 2025-08-01 | 加拿大商酵活英屬哥倫比亞有限公司 | 抗ｎａｐｉ２ｂ抗體－藥物結合物及使用方法 |
| WO2025199352A2 (en) * | 2024-03-20 | 2025-09-25 | Juno Therapeutics, Inc. | Antibodies specific for solute carrier family 34 member 2 (slc34a2) |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| CH694588A5 (de) | 1999-02-09 | 2005-04-15 | Hoffmann La Roche | Menschliche intestinale Npt2B. |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20030162254A1 (en) | 2002-01-15 | 2003-08-28 | Peerce Brian E. | NaPi type IIb polypeptides and methods for making and using same |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| WO2005101017A1 (en) * | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| MXPA06014065A (es) * | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| BRPI0716319A8 (pt) | 2006-10-25 | 2019-02-05 | Aovatechnologies Inc | método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano |
| WO2009097128A1 (en) * | 2008-01-29 | 2009-08-06 | Ludwig Institute For Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| US8742076B2 (en) | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| WO2010009124A2 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| JP5370826B2 (ja) * | 2009-04-20 | 2013-12-18 | 株式会社パソロジー研究所 | 癌の組織型を判別するカクテル抗体、判別キット及び判別方法 |
| PE20121584A1 (es) * | 2009-11-30 | 2012-11-29 | Genentech Inc | Composiciones y metodos para el diagnostico y el tratamiento de tumores |
| EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827327B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| JP5827326B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| EP2654769B1 (en) * | 2010-12-14 | 2020-04-15 | Recepta Biopharma S.A. | Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to napi2b transporter |
| CA2837840C (en) * | 2011-06-10 | 2020-08-04 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| KR102087850B1 (ko) * | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| KR102572149B1 (ko) | 2013-10-11 | 2023-08-30 | 아사나 바이오사이언시스 엘엘씨 | 단백질-폴리머-약물 접합체 |
| EP3906921A1 (en) * | 2014-04-25 | 2021-11-10 | Exelixis, Inc. | Method of treating lung adenocarcinoma |
| TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| JP6812364B2 (ja) | 2015-06-03 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌診断用抗ｇｉｔｒ抗体 |
| CA2991799A1 (en) * | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| EP3365679B8 (en) * | 2015-10-23 | 2021-03-10 | Roche Diagnostics GmbH | Methods of identifying an individual as to be treated by chemotherapy based on marker molecules and related uses |
| US20170261766A1 (en) | 2016-03-14 | 2017-09-14 | Vance M. Thompson | Contact lens with flexible center and rigid periphery |
| WO2017160753A1 (en) | 2016-03-14 | 2017-09-21 | The Penn State Research Foundation | Novel selenazolidine and thiazolidine compounds for treating cancer and other diseases |
| BR112018068461A2 (pt) * | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| US10772971B2 (en) | 2017-06-22 | 2020-09-15 | Mersana Therpeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
-
2018
- 2018-09-20 KR KR1020207011297A patent/KR20200055770A/ko not_active Abandoned
- 2018-09-20 US US16/136,706 patent/US11596694B2/en active Active
- 2018-09-20 WO PCT/US2018/051951 patent/WO2019060542A2/en not_active Ceased
- 2018-09-20 MX MX2020003214A patent/MX2020003214A/es unknown
- 2018-09-20 BR BR112020005390-2A patent/BR112020005390A2/pt not_active IP Right Cessation
- 2018-09-20 TW TW107133186A patent/TW201929906A/zh unknown
- 2018-09-20 AU AU2018337947A patent/AU2018337947A1/en not_active Abandoned
- 2018-09-20 CA CA3075798A patent/CA3075798A1/en active Pending
- 2018-09-20 JP JP2020516740A patent/JP7279026B2/ja active Active
- 2018-09-20 IL IL273252A patent/IL273252B2/en unknown
- 2018-09-20 CN CN201880074734.0A patent/CN111492246A/zh active Pending
- 2018-09-20 EP EP18792596.1A patent/EP3685166A2/en not_active Withdrawn
-
2023
- 2023-01-26 US US18/160,012 patent/US20230355787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273252B2 (en) | Compositions and methods for predicting response to napi2b-targeted therapy | |
| Oude Munnink et al. | Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology | |
| CN105392800A (zh) | 抗cxcl1、cxcl7和cxcl8抗体及其应用 | |
| ES2753360T3 (es) | Anticuerpos contra PD-L1 y usos de los mismos | |
| TR201802659T4 (tr) | Folr1 kanser terapisinin etkinliğini arttırmak için yöntemler. | |
| JP2015533788A5 (enExample) | ||
| JP2015529199A5 (enExample) | ||
| CN104755501A (zh) | 与赖氨酰氧化酶样蛋白2(loxl2)相关的治疗和诊断方法 | |
| Kuhs et al. | Characterization of human papillomavirus antibodies in individuals with head and neck cancer | |
| DK2694972T3 (en) | PROCEDURES FOR PREVENTING AND IMPROVING GASTRIC CANCER SURVIVAL | |
| ES2900852T3 (es) | Métodos de detección y/o medición de anticuerpos anti-fármaco, en particular anticuerpos anti-fármaco que se presentan durante el tratamiento | |
| RU2016116773A (ru) | Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы | |
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| JP2014523920A5 (enExample) | ||
| RU2017136863A (ru) | Способы лечения рака легкого | |
| JP2023545359A5 (enExample) | ||
| WO2018178307A1 (en) | Improved immunogenicity assays | |
| EA037015B1 (ru) | Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело | |
| JP2020515876A (ja) | 肺癌検出のための組成物と方法 | |
| Poellmann et al. | Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment | |
| EA037027B1 (ru) | Применение и способ для профилактики или лечения рака желудка с использованием композиции, содержащей моноклональное прогастринсвязывающее антитело | |
| KR20210126057A (ko) | 암세포에 존재하는 케라틴 14(krt14)의 세포외 부분을 표적화함으로써 암을 치료하거나 예방하는 방법 | |
| JP2025509564A (ja) | 抗ｔｒｏｐ２抗体－薬物コンジュゲート治療のためのスコアリング方法 | |
| EP3485281A1 (en) | Method and means for detecting the level of total vegf-a | |
| JP2018516877A5 (enExample) |